That specifically treats my cancer mutation. Im sure there are many other victims who would benefit from this innovation, but they must be made aware. For some reason, that knowledge is not being disseminated the patient. I do not know why. It could be regulatory. It could be insurance. It could be government obstacles. I do not know. But, i do know it could save lives. I can only adjust my treatment. Genomic testing work for me, it may not work for all. It is time to invest, and educate with these new innovations in mind. Science is moving rapidly. Traditional medicine in the past currently followed me to change. They need to change now. Back that can be up to you. I strongly believe that with science and funding, all patients will be treated with genomic testing. Though, the cure for cancer may remain elusive, the ability to live and thrive with cancer is well within our reach. Thank you for this opportunity. You have heard from the experts. What i would like to do now is introduce you to the Cancer Innovation coalition, and to have you understand what its mission and purpose is. I would also like to invite you to become very engaged and help us finding solutions, so that in these, we can secure the future of innovation and cancer therapy. The Cancer Innovation coalition was established in january 2014 by that National Patient advocacy foundation. Initially, the american cancer society, friends of Cancer Research, and the cancer community, nurses, business leaders, pharmaceutical companies today, our membership number 65 national organizations. Each committed to working successfully to secure their future of cancer therapy. The Cancer Innovation coalition will focus on legislative asked for 2013. There is a call today in which the coalition will determine its call for 2015. There is terminus focus on what we need to do on Clinical Trial design. There will be tremendous focus on the need for genetic testing and reimbursement for this, aand continued advanced research in the field of genomics. There also be varied with focus in the area of transparency and axis. As we know, that Affordable Care act has provisions that we should cover both trials. However, rulemaking on main street meaans we have very diverse interpretations of what will be paid for and not paid for in the Clinical Trial space. It is important that we look at the issue of transparency. In the Affordable Care act, we call for transparency. We call for transparency that will not pose any form of discrimination to any member of our society. Today, we have health plans that are developing pathways. They are in sending physicians to financial compensation. If they prescribe these pathways for their patients, that could be a good process. We do not know. A clear definition, what is the process of determining a pathway and what options are you including in the pathway and what options are you eliminating. We know that as we look at the Cancer Innovation coalition, and the work that we have ahead of us, we must understand betterhow the United States can handle a cancer population annually up 2. 3 Million People. If we look at the friends of Cancer Research initiative in collaboration with the fda and the nci, and multiple members of the pharmaceutical and biotechnology industry what we see is a new collaboration. Were leveraging Lessons Learned and resources across a number of frameworks and the goal of shortening the period of time it takes to accrue patient trials. Shortening the outcome of the trials. Two. A time in which we can cut those cost dramatically for the United States. We know that if we are spending 48 of all Research Dollars in the effortto accrue Clinical Trials, part of the solution is legislative and Regulatory Guidance that allows us to create new and diverse Clinical Trial models, and to be a will to remove drugs to market more quickly. We also know that in the United States, if we are to secure the future of innovation, we have a model that we can look at in the united kingdom. Into that someone, the accrual rate to Clinical Trials was at 3 in the united kingdom. The government said, we have to change something. We are losing our citizens to this disease called cancer. Since 2001, they have established the national Clinical Trial network in which every Clinical Trial is registered. Easy instructions on how to enroll. They then couple that with the creation of the national Clinical Trial registry, through which, if i had interest in funding a Clinical Trial, and you had interest in funding the same Clinical Trial, we can register with that body we will be partnered together, and introductions will be made. So, today we have multiple trials in that country that include multiple manufacturers, multiple nonprofits, and the government. They have to move their accrual in Clinical Trials since 2001 now to 17 annually. The United States is a nation of compassion. It is a nation of sensitivity to the needs of its population. It is a nation that wants to embrace the future and make life better for everyone in this country moving forward. One way that we can do that is to deal with securing innovation in the field of cancer. Lets remove the statistics about the 70 of families that had a cancer diagnosis will move into bankruptcy within six months of diagnosis. Lets get rid of that. Lets get rid of the statistics that say were not finding what we need. You are in a position in the United States congress to work with us, to have introduced Regulatory Reform measures that can improve what we have currently in statute. You are in a position in congress to introduce new legislation, tthat can perhaps and sent new Clinical Trial design, more funding for research bodies. We have lost 20 of funding to our federal agencies whose job are to start the research at the bedside. That is where begins. No one can step forward and fill that gap. When you combine 20 of loss of revenue with the escape of venture capitalists to foreign markets you can see where we are today in the United States. 70 of our Clinical Trial accruals are happening overseas. 30 are occurring in the United States. That means we lose jobs, we lose revenues, and the patient to call us who are desperately ill and need options that are not in the market they are often denied that access if the trial is being operated in another country. Do Cancer Innovation coalition, and project innovation, we will be moving forward with multiple regulatory and legislature asks in 2015. We want to partner with each of you who are in his room. We need your ideas, and the ideas of the bosses that you represent, and the communities that they represent, and the constituents in your districts. On february 11, we will be at the National Press club. At that point, we will announce to america the blueprint of the Cancer Innovation coalition. We are working with them is United States congress and officials to shape that today. Im pleased to have had the opportunity to give it some academic background on the Cancer Innovation coalition. We will take questions and answers immediately after we hear from one Additional Group of experts, including dr. Woodcock from the fda. This is an exciting time because we have the opportunity to make the most advanced clinical decisions available to every cancer patient regardless of where they live or the socioeconomic background, and regardless of what practical resources they may have available to them. I think now, innovation is so important. There is an expectation, next vacation from patients. There is really an expectation that patients have for the latest technology and features. In this era of personalized medicine and diagnostics many many unique targets have been defined to treat cancer. We cannot afford to innovate. We cannot afford to put up with the status quo. I think we are on the cusp of an information revolution. The information revolution in medicine will be transformative. In my 30 years as an oncology nurse, there have been advances that have gone from being totally un curable to one year survival, now two years and years of survival. I think we have the knowledge now to continue with the research that we have been doing to make cancer a disease that very few people die of. Therapy in cancer is a revolution now, targeted therapy requires development of diagnostics, as well as targeted treatment. We need better data. We need personal data about everyones genetic makeup, so we can use that information literally in the individual war on cancer for each patient. It is critical that we get patients involved. Also leveraging things like Electronic Health records to help us see what has been tried, and what could be tried. We needed need to get survival rate to a better place. So, you have heard from a number of people today. Now it is your turn. What well would like to do is invite you to address your questions to any of our panelists. The floor is open for questions. If you could, go to the microphone in the center of the aisle. If we have left you speechless that could be a good thing. If we have left you energized, and that is even a better thing. I would say, you certainly have our contact information. Dont hesitate to advance your questions, your ideas it will take all of us together to develop a strategy to improve innovation in cancer for 300 Million People in this United States. Thank you so much for your time and attention. Thank you, congressman scott, for being with us. Heather, the patient always gets it right. My colleague from National Patient advocate foundation, thank you. Have a good day. [captions Copyright National cable satellite corp. 2014] [captioning performed by the national captioning institute, which is responsible for its caption content and accuracy. Visit ncicap. Org] monday night on c span. A Funeral Service for ben bradlee, former Washington Post journalist. Speakers include bob woodward. He broke the watergate story. On september 23, 1972, about 9 00 pm, i spoke to John Mitchell about a story that we are writing. He said that he had controlled a secret funds for undercover operation such as watergate. Mitchell was quite upset. He responded, jesus several times as i read the story. Key then went on to threaten if the post were to publish a story. He also said, we will do a story on all of you, he hung up the phone. I called ben at home. Woodward and id did not observe the changing commands. Had mitchell been drinking . I couldnt tell. To did i properly identify myself . Yes. Tell the desk it is okay, he said. A top official of the Nixon Campaign called me a few minutes later to make an appeal that mitchell had been caught in an unguarded moment. He has been a cabinet member, and so forth he doesnt want to show up in the paper like that. An official called bravia home to repeat that appeal. Bradley recalled that it boils down to this question of whether or not mr. Mitchell said it or not, and whether the Washington Post reporter identified himself or not. Mitchells comments stayed in the paper. Ben bradlee served as the editor of the Washington Post for more than 30 years. He died in october of the age of 93. We will have is Funeral Service on monday night on c span. New years day on the c span network. Here are some of our future programs. New years day on the c span networks. For a complete schedule go to c span. Org. When the new Congress Begins in january, it will be the first time that there are more than 100 women lawmakers. Of the 84 women in the house, 22 will be republicans, and 62 democrats. Meanwhile, the senate will have a total of 20 women. Among them are the senator of utah she marks another first, the first African American woman in congress. These members of congress will be sworn in in just over one week from now. From washington journal, this is 45 minutes. Host at the table now good morning looking forward to this year, both chambers will be headed by republicans. What are your expectations . Guest we have seen as hand to hand combat with the present over the last several years. Republicans have not had the house since 2011. I think republicans will start with a flurry of activity. They may try to pass Something Like the keystone xl pipeline. They will pass some tax law changes. Talk about maybe rolling back some of obamas regulatory onslaught. I think you will see the question right now is whether or not present obama will be in the mood to compromise, or if there will just be more partisan battles. Clearly after the 2010 midterm elections, when republicans took the house, the present did not move to the middle. We may see some of that over the next 18 months. Host our guest is the author of five books. He has been on this program a number of times. He is founder and president of the growth club. We are here time of the 114 congress it starts up and about 10 days. There will be a lot of activity. We will put the phone numbers on the bottom of the screen. We do want to go do something about keystone, which you talked about. Senator mcconnell talked recently about keystone and where it will be in the schedule. [video clip] we will be starting next year with a job creating bill that enjoys significant bipartisan support. The first item up in the next senate will be the keystone xl pipeline. It will be open senators on both sides will offer energy amendments. We will move forward, and hopefully be able to pass it. It is a very important job creating bill in the session. Host wife why is keystone so important . Guest; the biggest story in the last several years has been that Energy Revolution. The United States have moved to become the biggest oil and gas supplier. The shell gas revolution is moving all over the country. It has power the economy in many ways. I think this Energy Revolution is what is causing prices to fall. Here is what is critical we need pipelines to get energy to the places where we are producing it to the places where we needed. We need to not only get all over the United States, but also exporting it. In the next five years, the United States will become an oil and gas import country to an oil and gas export country. I would make another point this is clearly about jobs. This would make 10,000 to 15,000 jobs. These are union jobs. Theres no reason not to do this. Someone might say that might be spilled from the pipelines there always dangerous in the situations. It is pretty clear that is much safer to transfer oil and gas through pipelines than on trucks. Wwe do not need just the keystone xl pipeline, we need an network of pipelines. Host it was a pretty close vote. Would there be a vetoproof majority . Guest that is a great question. Many people say that mary landrieu, who lost her voice, many people think that the reason she lost this because the democrats voted that down. This is a bill that 70 of americans support. By the way, the present talked every speech he gives on the economy, he talks the infrastructure. We need pipelines in this country. This project will not cost the taxpayers a penny. Host before we go to calls, you mentioned tax reform. Will 2015 be the year for something significant . Guest that is a tough question. Republicans clearly want to do something big. I think 2017, after the next president ial year, will be the time when we start over with the tax system. 2015 could be the year we get something on the business side. Remember, the United States has a high statutory tax rate in the world a lot of economist, like myself, think that puts the United States at a disadvantage. Host steve moore is the chief economist at the Heritage Foundation. What has it been transitioning to place like heritage . Guet it has been great. It is one of the most important think tanks in the country. We meet regularly with members of congress. We have an action team that is trying to promote ideas on capitol hill. It is based on the economy, free markets of course we believe in strong defense. I think we will have a powerful voice in the years to come. Host lets get dale on the line. What would you like to say to Stephen Moore . Caller you know, i had a job for the last two years ggas prices drop down to about half, why . Guest that is a grace question, why. I think what we just talked about is the reason. The big change over the last six